Oncology

Cancer therapeutics including targeted therapies, immunotherapies, cell therapies, and precision oncology platforms.

Companies

Pipeline Drugs

7991

Key People

9469

Oncology Pipeline (7991 drugs)

Pre-clinical: 1044Commercial: 1038Preclinical: 952Phase 1: 615Phase 2: 385Approved: 371Phase 3: 299Phase 1/2: 278Discovery: 248Research: 191Development: 184Marketed: 82Phase III: 79Phase 2/3: 53Discovery/Preclinical: 51Clinical: 50Phase I: 46Phase 1b: 43Phase II: 37Unknown: 35Not Specified: 34Service: 34Phase I/II: 32Not Disclosed: 29Clinical Validation: 28Development/Commercial: 28N/A: 28Development/Validation: 27Phase 1b/2: 26Launched: 26Discovery/Pre-clinical: 25Phase 2b: 23Pre-clinical/Development: 23IND-Enabling: 22Phase 1/2a: 21Research/Pre-clinical: 20Approved/Commercial: 19Research/Development: 19Pre‑clinical: 18Phase 2a: 17commercial: 17Market: 17Preclinical/Phase 1: 16Regulatory Review: 16Research-Use Only: 16Not specified: 15Commercial/Development: 15Pre-Clinical: 14Phase 1b/2a: 14NDA Submitted: 13Preclinical/Research: 12Clinical Trial: 12Service Offering: 12Preclinical/Discovery: 11Lead Optimization: 11Pivotal Trial: 11Research/Discovery: 11Early-stage Clinical: 11R&D: 10Clinical Development: 10In Development: 10Research/Preclinical: 9Pre-clinical/Clinical: 9IND-enabling: 8Research Use Only: 8Pre-commercial: 8Pre-clinical/Clinical Validation: 8DiscoverY: 8Commercial & Development: 8Approved / Phase 3: 7Regulatory: 7Clinical Trials: 7Commercial/Service: 7IVD: 7Clinical Investigation: 6Commercial Launch: 6Pivotal: 6Discovery/Validation: 6Pre-IND: 6Research-Use-Only: 6Research & Development: 6Pre-market: 6Pre-clinical/Early Clinical: 6Phase II/III: 6Early Phase: 6Phase IIb: 5CE-IVD Marked: 5Phase I/IIa: 5Randomized Controlled Trial: 5Observational Study: 5Pre-clinical Tool: 5Clinical Research: 5Phase 1a/1b: 5Exploratory: 5Phase 2B: 5Validation: 5Clinical Study: 5Pre-clinical/Research: 5Pre-clinical/Phase 1: 5Phase 0: 5RUO: 5ANDA Filed/Approved: 5ANDA Pending: 5Commercial/Ongoing Validation: 5Process Scale‑up: 4Phase 2b/3: 4Phase Ib/II: 4Preclinical Research: 4Preclinical/Development: 4Reference Standard: 4Research/Validation: 4Feasibility: 4Phase 1a: 4All Phases: 4Not Applicable: 4Pilot: 4Planned: 4Pre-clinical/Validation: 4IND Enabling: 4Commercial Model: 4Feasibility Study: 4Early Clinical: 4LDT: 4Tool/Platform Development: 4ANDA Approved: 4Clinical (Phase not specified): 4Assay Development/Validation: 4Commercial Expansion: 4Licensed: 4FDA-Cleared: 4Platform/Partnership: 4Preclinical / Early Clinical: 4Phase 1/1b: 4Under Development: 3Preclinical/IND-enabling: 3Discovery/Development: 3IND Approved: 3Partnership Development: 3Various: 3FDA Approved: 3Phase IIa: 3Post-Market Registry: 3Ongoing Development: 3Poised for Clinical: 3Commercial (LDT): 3Platform: 3Platform/Tool Development: 3Early Discovery: 3Non-Clinical: 3Platform / Asset: 3Phase 1a/b: 3Assay Development: 3Proof-of-Concept: 3Discovery in Vitro: 3Research/Commercial Tool: 3Pre-clinical/Discovery: 3Commercial Deployment: 3Development/Commercialization: 3Discovery/Optimization: 3NA: 3Research/Assay Development: 3Observational: 3Pre-clinical (inferred): 3RUO Kit: 3Preclinical/Phase 1/2: 3Phase 2 Ready: 3Early Development: 3Post-Market: 3Research-Use: 3Preclinical/Early Clinical: 3Development/Accreditation: 3RUO Commercial: 3Lead ID: 3Approved (CE/UKCA): 3Preclinical through Commercial: 3Phase 4: 3NDA Filed: 3Early clinical trial: 3Commercial/Platform: 3Clinical POC: 3CE‑marked: 3Preclinical/Phase I: 3Approved / Lifecycle: 3IND Cleared: 3Undisclosed Preclinical/Discovery: 3Early Preclinical: 2Phase 1/IIa: 2Formulation Development: 2Commercial-Ready: 2IND Filed: 2ANDA Filed / Development: 2Approved/Marketed: 2Marketed (EU): 2Registrational: 2Regulatory Filing: 2Clinical (China & US): 2Pivotal Study: 2IND enabling: 2Commercial Service: 2Research Tool: 2Pre-clinical / Phase 1: 2Preclinical/Translational: 2Prototype: 2Product Launch: 2Commercialization: 2Research/Exploratory: 2Commercial / Clinical Development: 2Hit-to-Lead: 2Preclinical or Early Clinical: 2Discovery/Research: 2Proof of Concept: 2Phase 2/Phase 3: 2Phase 1B: 2N/A - Service: 2N/A (Diagnostic Validation): 2Pilot Study: 2Pre-launch: 2Phase not specified (Clinical/Preclinical): 2Phase 3 / Marketed: 2Development/ANDA Filing: 2Clinical (Phase unspecified): 2FDA Cleared: 2Design & Development: 2Phase not specified: 2Biomarker Development: 2Pre-clinical/Exploratory: 2Phase 1 (Planned): 2Not Applicable (Service Provider): 2Pre-clinical / Early Clinical: 2Pre-clinical / Phase 1 implied: 2Commercial (FDA EUA): 2Development/Partnership: 2Clinical-stage: 2Phase 1/Phase 2: 2Research / Development: 2Pre-clinical / Phase 1 pending: 2Development/Clinical Trials: 2Breakthrough Device Designation: 2Clinical Feasibility: 2Clinical Utility Study: 2Preclinical/Clinical: 2Validated: 2Development/Regulatory: 2Diagnostic: 2Trial: 2Phase 3 (inferred from ASH presentation): 2Development/Marketed: 2Preclinical to Clinical: 2Phase 3 / Registration: 2Undisclosed: 2Preclinical (IND candidate): 2Observational Validation: 2Clinical Use: 2FDA‑cleared: 2Pre-registration: 2Approved / Phase III: 2Phase III / Marketed: 2Phases I-III & Commercial: 2Development & Commercial: 2Approved (EU): 2Phase III / NDA: 2Pivotal Phase 2: 2Research Use: 2Interventional Study: 2Observational Cohort Study: 2Phase 3-ready: 2Clinical Review: 2Commercial/Validation: 2Various (Partner-led): 2BLA Submitted: 2Clinical use (TFDA‑approved LDT): 2Indication Enabling: 2Phase I / II: 1Phase IIb/III: 1Commercial (CE‑certified): 1Late‑stage validation: 1IND Accepted: 1Pivotal Trials: 1Early-stage: 1Approved (CE Mark): 1Approved (EUA): 1Clinical Trial (Phase not specified): 1Commercial & Clinical Support: 1Ongoing R&D: 1Pre-clinical / Early Development: 1ANDA Pending / Development: 1Marketed / Line Extensions: 1Pre-commercial/Development: 1Phase Ib/IIa: 1Approved / Marketed: 1Approved (Conditional - AU): 1Commercialization / FDA Pathway: 1Assay Development / Validation: 1Commercial (B2B): 1Phase III/Commercial: 1Pilot Clinical Trial: 1Dose-Finding Study: 1Development & Validation: 1Continuous Development: 1Approved (EU) / Phase 3 (US): 1Approved (RA) / Phase 3: 1Pipeline: 1Clinical stage (specific phases not disclosed): 1Commercial (Iterative): 1Approved (Japan): 1Phase 1b/3: 1Phase 3 / BLA: 1Phase 1/2A: 1Lab-Developed Test: 1Limited Launch: 1R&D / Integration: 1Research Platform: 1Commercial (in China): 1preclinical: 1Clinical (pediatric trials): 1Phase I-III: 1Phase IV: 1Safety & Effectiveness Study: 1Investigational Study: 1Feasibility Trial: 1Randomized Controlled Study: 1Development/Commercial (LDT): 1Investigator-Initiated Trial: 1Clinical Adoption: 1Clinical trial: 1Pre-production/Prototype: 1Advanced Development: 1Commercial Tool: 1Platform/Service: 1Service/Diagnostic: 1Platform/Pre-clinical: 1Approved (NPIP): 1Pilot/Phase 2: 1Component: 1R&D/Collaboration: 1Early-Stage (FIH/EFS): 1Early Clinical Development: 1First-in-Human (FIH): 1Under Review: 1R&D / Early Clinical: 1Research & Regulated Studies: 1Trial Completed: 1Commercial / PMA Submission: 1Early Feasibility / Safety: 1Proposed Acquisition: 1Phase 1/Window-of-Opportunity: 1Clinical-Stage: 1ANVISA Submission/Commercial: 1Phase 3 (preparing): 1Commercial Update: 1Strategic Initiative: 1Pre-clinical to Phase 3 (Bioequivalence): 1ANDA Development/Commercial: 1Development for FDA Approval: 1Portfolio spans Pre-clinical to Phase 1: 1Service/Platform: 1Preclinical/Clinical (unspecified): 1Development (with GenScript): 1Development/Regulatory Clearance: 1Pre-clinical (partnered): 1Post-market: 1Feasibility Trial Completed: 1IND-Prep: 1Optimization: 1CE Mark (EU); Research Use Only (US): 1ANDA Filed/Pre-approval: 1Service Platform: 1First-in-Human / Clinical: 1CE Marked: 1Phase 2/3 (investigational): 1Process Development/Technology Transfer: 1Observational Trials: 1Launching: 1Commercial/Research: 1Pre-NDA: 1Not Specified (Preclinical-Phase 2): 1Clinical (phase unspecified): 1Integration/Development: 1Preclinical/Clinical Development: 1Discovery through Preclinical: 1IVD Kit: 1Clinical Use (Investigational): 1Development/NDA Filing: 1Development/DMF Submission: 1Commercial Integration: 1Pilot Clinical Studies: 1Pre-clinical/Clinical Trial Preparation: 1Pre-clinical/Clinical Feasibility: 1FDA Qualified for Trials: 1Phase not specified (Clinical): 1Advanced Commercialization/Validation: 1Trial Support: 1Commercial (Early Access): 1Device Development: 1In Vivo Discovery: 1Pre-clinical/Platform: 1Validation Study: 1LDT/Service: 1Facility Development & Licensing: 1Development/Prototype: 1Proof of concept: 1Market Development: 1Clinical Validation/Service Launch: 1Regulatory Submission (OECD): 1Commercial (as LDT): 1Phase 3/Registrational: 1Development/Scale-up: 1Hit to Lead: 1Late-stage (Animal Rule): 1Work in Progress: 1Pivotal Clinical Trial: 1Clinical Studies: 1Commercial/CMO: 1AI Discovery: 1Development Candidate: 1Phase 3 (planned): 1Phase 2 (planned): 1Research/Clinical: 1Development (Phase 1 Complete): 1NDA: 1Approved/RUO: 1Collaboration: 1Development/Pre-market: 1Lead Optimisation: 1Development/Construction: 1Test Stage: 1Pre-ANDA: 1Commercial / Generic Development: 1Early Access: 1Approved/Commercial (in Latvia): 1ANDA Development/Filing: 1Phase 2 (based on prior studies; current development stage unclear): 1Pre-clinical/Feasibility: 1Approved/Clinical: 1Pre-clinical to Commercial: 1Development/Pre-clinical: 1Research Collaboration: 1N/A (Interventional Trial): 1Various (Pre-clinical to Phase 3): 1Not Specified (Orphan Designated): 1Development & Clinical Research: 1CE Mark Approved: 1Phase 1-ready: 1Research / Aspirational: 1Commercial/Iterative Development: 1Commercial (CLIA LDT): 1Approved/Expanded Access: 1Platform/Research: 1Proof-of-Principle: 1Completed R&D: 1Business Development: 1Research/Concept: 1Clinical (Partnered): 1Phase 2 Planned: 1Pre-clinical/Proof-of-Concept: 1Class II Medical Device: 1Range from Pre-clinical to Late-stage: 1Preclinical Discovery: 1Market Launch: 1Pre-clinical / Phase 1 (Initiating): 1Phase 2A: 1N/A (Early Access Program): 1N/A (Commercial/Expanded Access): 1N/A (Donation/Distribution Program): 1IND-ready / Pre-clinical: 1Preclinical/Proof-of-Concept: 1Pilot Observational Study: 1Post-Market Study: 1NA (Pivotal Trial): 1NA (Investigational): 1NA (Investigational Use Only): 1Pre-clinical/Clinical Study: 1Discovery to Pre-clinical Candidate: 1Clinical (exact phase unspecified): 1Early stage / Investigator Trials: 1N/A (Diagnostic Service): 1Phase 1b (planned for 2026): 1Pre-clinical / CTA Cleared: 1Research/Design: 1Pre-clinical / Phase 1 (OASIS Trial referenced): 1Development/Commercial Launch: 1Development Agreement / Pre-Clinical? (Combination Study): 1IND ready: 1Development/Discovery: 1ANDA Development / Commercial: 1Pre-clinical/Clinical (Phase not specified): 1Development/Early Access: 1Commercial/Research-Use: 1Development/Launch: 1Validation/Commercial: 1Clinical-stage (Phase not specified): 1RUO/Clinical LDT: 1Research/Development & Commercial (EUA for COVID-19): 1Pre-clinical/Clinical Development: 1Licensed/Orphan Designation: 1Phase 2/Spin-out: 1Development/Commercial Expansion: 1Phase 3 Planning: 1Pre-clinical/Clinically Ready: 1Not Specified (Acquired Pipeline): 1Commercial (Iterative Updates): 1Commercial (New Module Release): 1Pilot Studies: 1Phase 1-4 (as component): 1Research / Pre-clinical: 1Approved (ex-US) / Investigational (US): 1Pivotal Trial (Phase 1 Completed): 1Veterinary INAD-stage: 1Development & Commercialization: 1Phase 3 (Partner sought): 1Applied Research/Service: 1ANDA Submitted / Approved: 1Clinical Validation / Regulatory: 1Varies by Sponsor Protocol: 1Platform Validation: 1Diagnostic Development: 1Service/Commercial: 1Commercial/Implementation: 1Pre-market Approval (FDA Breakthrough): 1Pre-clinical / Feasibility: 1Commercial (Recent Acquisition): 1Discovery/Hit-to-Lead: 1IND Approved / Phase 1 Planned: 1Phase 1b/2 (planned): 1Prototype / Clinical Testing: 1Conceptual / Early Development: 1Investigational: 1Phase 2 (next-gen): 1BLA Resubmission: 1cGMP Production: 1Scale-Up: 1Phase 1/2 (Planned Cohort): 1Pre-clinical (based on prior clinical experience): 1Partnership/Development: 1Clinical Trial (partner-led): 1Phase 2-ready: 1In-vivo: 1In-vitro: 1Phase Ib: 1Prospective Clinical Trials: 1Phase 2/3 (Pivotal planning): 1Pivotal/Phase 3: 1Pivotal (FDA IDE): 1Service Commercial: 1Pre-clinical/R&D: 1Diagnostic/Research: 1Research Service: 1IND filed: 1Integration & Development: 1Clinical Stage (Phase unspecified): 1Lifecycle Management: 1Service/Development: 1Registration/Clinical: 1Not Applicable (Client product): 1Device Commercial/Clinical Use: 1Clinical Trial (Partner-led): 1Phase 0/1: 1Discovery/Pre-Clinical: 1Phase 1/II: 1Commercial Preparation: 1Clinical Evaluation: 1Approved (in China): 1Research to IND: 1Development/CE Marking: 1Commercial/Market Expansion: 1R&D/Validation: 1Partnership/Regulatory: 1Registration: 1Development/Production: 1Development/Industrialization: 1Commercial (RUO): 1PMA Review: 1Evaluation: 1Phase I (Completed): 1Platform/Product: 1Research/Platform: 1RUO/Clinical Research: 1IVD/CE-Marked: 1Bioequivalence: 1Clinical-stage (phase unspecified): 1Ongoing Research: 1Real-World Evidence: 1Pre-clinical/Clinical Studies: 1Late-stage Development: 1Active: 1Preclinical (Phase 1 planned 2026): 1IND‑cleared (Phase 1 planned): 1Clinical trials: 1development: 1Preclinical (Mouse Studies): 1Preclinical/early clinical: 1Commercial (planned from 2024): 1Pre‑launch: 1Phase 1/III: 1Investigator‑initiated trial: 1Pre‑clinical / IND filing: 1510(k) cleared: 1Clinical Validation Completed: 1FDA‑cleared (commercial): 1CE‑marked, FDA‑cleared (commercial): 1CE‑marked, clinical registry: 1Clinical use: 1Available: 1NDA filing: 1Not Specified (Commercial/Registration): 1Filed/Phase III: 1Multiple (I-III): 1Launched/Phase 3: 1Preclinical to Phase 2: 1Launched / Phase 3: 1Filed (US): 1Varies: 1Filed/Approved: 1Development/Filed: 1ANDA Filed: 1Approved/Phase III: 1Discovery through Commercial: 1Preclinical through Clinical: 1Application Submitted: 1BE Studies / Scale-up: 1Preclinical / Early Development: 1Phase 3 / Approved: 1Commercial / Development: 1Discovery / Preclinical: 1Clinical/Commercial: 1NDA Resubmitted: 1Marketed/Development: 1Regulatory (EU): 1Commercial & Line Extensions: 1Phase II / Phase III: 1Phase I / Phase II: 1ANDA Submitted: 1Late-Stage (Phase 3): 1Discovery / Preclinical / Early Clinical: 1Marketed (ex-US): 1Clinical Evidence Generation: 1Translational Studies: 1Collaborative Development: 1Data Analysis: 1Ongoing Validation: 1Preclinical / Phase 1 (planned): 1Multiple Phases 1/2: 1Pivotal Studies: 1Filed: 1Phase 1/2/3: 1Marketed / Late-stage Study: 1Pre-Clinical to Clinical: 1IVD Submission: 1Marketed / Phase 3: 1Regulatory/Commercial: 1Phase not specified (Class 1 New Drug): 1Not specified (API/Formulation): 1Preclinical / Phase 1: 1Registration & Launch: 1Development & Registration: 1Technology Transfer & Localization: 1Exploratory / Early Development: 1Phase 1/2 (Inferred): 1Phase 1 (Inferred): 1Prospective Cohort Study: 1Observational Case-Control Study: 1CLIA LDT: 1510(k) Submission: 1Feasibility Study & 510(k) Submission: 1Authorized: 1Level I Clinical: 1Research Program: 1Discovery to Clinical: 1Preclinical to Commercial: 1Commercial/Early Launch: 1Phase 2b Planned: 1Research/Pharma Services: 1Phase I / Early Clinical: 1Preclinical / Phase I Prep: 1BLA Filed: 1BLA Submission: 1Late Preclinical: 1Phase 2 / Pivotal: 1Launch Preparation: 1Phase I to Phase III: 1IND Submitted: 1Commercial Initiative: 1FDA 510(k) Submission: 1Clinical Research / LDT: 1R&D/Clinical Studies: 1Preclinical (IND granted per timeline): 1Phase 3 Ready: 1Pre‑clinical development: 1Not Specified (Likely Clinical): 1Veterinary: 1Phase 2/Planned Phase 3: 1Clinical Trial (phase not specified): 1Research/Commercial: 1Investigator-Initiated Trials: 1Approved (China NMPA Review): 1Phase 1/2 / Pivotal Path: 1sNDA Review: 1Phase 2/1b: 1Phase 1b (assumed): 1Preclinical/Partnership: 1Prescription Product: 1

Drug	Company	Indication	Phase	Status
CM24	Purple Biotech	Non-Small Cell Lung Cancer	Phase 2	Active
NT219	Purple Biotech	Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma	Phase 1/2	Active
Mipletamig (APVO436)	Aptevo Therapeutics	Acute Myeloid Leukemia (AML)	Phase 1/2	Active
ALG.APV-527	Aptevo Therapeutics	Solid Tumors (5T4+)	Phase 1	Active
APVO603	Aptevo Therapeutics	Solid Tumors	Preclinical	Active
APVO711	Aptevo Therapeutics	Solid Tumors	Preclinical	Active
APVO442	Aptevo Therapeutics	Prostate Cancer	Preclinical	Active
APVO455	Aptevo Therapeutics	Solid Tumors (Nectin-4+)	Preclinical	Active
APVO451	Aptevo Therapeutics	Solid Tumors (Nectin-4+)	Discovery	Active
APVO452	Aptevo Therapeutics	Prostate Cancer	Discovery	Active
CY-101	Cytovation	Adrenocortical Carcinoma	Phase 2	Initiate 2H-25
CY-101 + Pembrolizumab	Cytovation	Colorectal Cancer	Phase 1/2	Initiate 1H-26
CybroCell™	FibroBiologics	Degenerative Disc Disease (DDD)	Phase I / II	FDA IND Cleared
CYMS101	FibroBiologics	Multiple Sclerosis (MS)	Preclinical	Active
CYWC628	FibroBiologics	Wound Healing	Discovery	Active
CYPS317	FibroBiologics	Psoriasis	Discovery	Active
CYTER915	FibroBiologics	Cancer Immunotherapy	Discovery	Active
TBC190	FibroBiologics	Thymic Involution	Discovery	Active
Herceptin (Trastuzumab) Biosimilar	NeuClone	HER2‑positive Breast Cancer	Phase 1	Active
Stelara (Ustekinumab) Biosimilar	NeuClone	Psoriasis / Crohn's Disease	Phase 1	Active
Perjeta (Pertuzumab) Biosimilar	NeuClone	HER2‑positive Breast Cancer	Process Scale‑up	Active
Opdivo (Nivolumab) Biosimilar	NeuClone	Various Cancers (PD‑1 inhibitor)	Process Scale‑up	Active
Keytruda (Pembrolizumab) Biosimilar	NeuClone	Various Cancers (PD‑1 inhibitor)	Process Scale‑up	Active
Prolia/XGEVA (Denosumab) Biosimilar	NeuClone	Bone Metastases / Osteoporosis	Process Scale‑up	Active
Humira (Adalimumab) Biosimilar	NeuClone	Autoimmune Diseases	Early Preclinical	Active
Synagis (Palivizumab) Biosimilar	NeuClone	RSV Prophylaxis	Early Preclinical	Active
Cell-in-a-Box® + Ifosfamide	PharmaCyte Biotech	Locally Advanced Pancreatic Cancer (LAPC)	Phase 2b	On Hold
Cell-in-a-Box® Insulin-Producing Cells	PharmaCyte Biotech	Type 1 & Insulin-dependent Type 2 Diabetes	Preclinical	On Hold
Piclidenoson (CF101)	Can Fite Biopharma	Plaque Psoriasis	Phase III	Active
Namodenoson (CF102)	Can Fite Biopharma	Hepatocellular Carcinoma	Phase IIb/III	Active
CF602	Can Fite Biopharma	Erectile Dysfunction	Preclinical	Active
Oncology Vaccine Program	CHAIN Biotech	Oncology (unspecified)	Pre-clinical	Active
Anti-infective Vaccine Program	CHAIN Biotech	Infectious Diseases (unspecified)	Pre-clinical	Active
Antifibrotic Therapy Program	MeCo Diagnostics	Breast Cancer	Pre-clinical	Active
BDC-4182	Bolt Biotherapeutics	Gastric Cancer, Gastroesophageal Junction Cancer (Claudin 18.2+)	Phase 1	Active, Enrollment Open
Macrophage-Targeting Agonist Antibody	Bolt Biotherapeutics	Undisclosed Solid Tumors	Phase 1	Available for Partnering
Preclinical ISAC 1	Bolt Biotherapeutics	Undisclosed	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Undisclosed	Preclinical	Available for Partnering
RASTRUM™ 3D Pancreatic Cancer Model	Inventia Life Science	Pancreatic D	Pre‑clinical	Active
RASTRUM™ 3D Alzheimer’s Disease Model	Inventia Life Science	Alzheimer’s disease	Pre‑clinical	Active
RASTRUM™ 3D Tumor‑Immune Co‑culture Platform	Inventia Life Science	Immuno‑oncology	Pre‑clinical	Active
GH31	Genhouse Bio	Oncology (specific tumors not specified)	Phase 1	Active (partnered with Gilead)
GH56	Genhouse Bio	Oncology (specific tumors not specified)	Phase 1	Active (investigator meeting held August 2025)
NUC-3373	NuCana	Colorectal Cancer, Biliary Tract Cancer	Phase 2	Active
NUC-7738	NuCana	PD-1 Resistant Melanoma, Advanced Solid Tumors	Phase 2	Active
NUC-8232	NuCana	Various Solid Tumors	Phase 1	Active
lomonitinib	Lomond Therapeutics	Acute Myeloid Leukemia (AML)	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Chronic Lymphocytic Leukemia (CLL)	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Acute Myeloid Leukemia (AML)	Discovery	Active
Systemic DNase I	Xenetic Biosciences	Pancreatic Carcinoma	Preclinical	Active